MarketBeat
26 Sept 2026, 21:02 UTC · 2h ago
Verdict
Headline leans bullish. We score WAT +0.90 across five claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish · 1 new · 4 priced in
Waters achieved a 9% organic growth rate in the second quarter, exceeding its 6% to 8% guidance range.
Priced indiscussion of Q2 performance at a JPMorgan event
So whatBeat of 100-300bps suggests a potential upward revision for FY2026 estimates.
More positive than 93% of claims this week
The company expects to reach a $200 million annualized cost-synergy run rate from Becton Dickinson businesses by year-end.
Continue reading
5 related stories
More positive than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced indiscussion of Q2 performance at a JPMorgan event
So whatAccelerating the 3-year target into 9 months significantly boosts EPS in Q4.
More positive than 87% of claims this week
Waters has visibility into instrument replacement demand through the end of 2027.
Priced indiscussion of Q2 performance at a JPMorgan event
So whatProvides a multi-year revenue floor that reduces the risk of a cyclical downturn through FY2027.
More positive than 79% of claims this week
The A7 spectral flow-cytometry instrument was launched on September 14.
Newlaunched on Sept. 14
So whatRevenue from this launch will first appear in the Q3 and Q4 prints.
More positive than 66% of claims this week
Pharmaceutical manufacturing reshoring is expected to become an incremental growth driver from 2027 through 2030.
Priced indiscussion of Q2 performance at a JPMorgan event
So whatLong-term tailwind that likely won't materially move margins until 2027.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
Exceeded Q2 expectations with 9% organic growth and strong progress in AI adoption and business integration.
More positive than 66% of ticker scores this week
The acquired businesses from BDX grew on average by 4% and are contributing to synergy targets.
More positive than 61% of ticker scores this week
Mentioned as having growth potential in the medical stocks sector.
More positive than 61% of ticker scores this week
Mentioned as having growth potential in the medical stocks sector.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
6h ago
More positive than 14% of relationship scores this week
[mutual] Both companies are mentioned together as showing growth potential in the medical/analytical science space.
More positive than 14% of relationship scores this week
[mutual] Both companies are mentioned together as showing growth potential in the medical/analytical science space.
—
WAT hasn't traded since this ran. Last close $433.54 (Sep 25); the reaction starts at the next open.
WAT chart →
